Vical (VICL), Astellas Announce ASP0113 Phase 2 Missed Primary Endpoint in Kidney Transplant Patients
Tweet Send to a Friend
Vical Incorporated (Nasdaq: VICL) and Astellas Pharma Inc. announced topline results from a randomized, double-blind, placebo-controlled Phase 2 study evaluating ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE